 TORONTO, Nov. 07, 2022 GLOBE NEWSWIRE -- Reunion Neuroscience Inc. NASDAQ: REUN, TSX: REUN Reunion or the Company, a biopharmaceutical company committed to developing innovative therapeutic solutions for underserved mental health conditions, announced today that it plans to release its business update and financial results for its fiscal 2023 second quarter ended September 30, 2022, before market open on Monday, November 14, 2022. 